Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

gemcitabine/SU5416

Known as: dFdC/SU-5416 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Rationale: The pathogenesis of pulmonary arterial hypertension (PAH) involves remodelling of the pulmonary arteries, increased… Expand
2017
2017
Background: SUGEN/hypoxia (SuHx) causes pulmonary hypertension (PH) in rats. Cardiac MR (CMR) is the gold standard for… Expand
2016
2016
The SU5416 + hypoxia (SuHx) rat model is a commonly used model of severe pulmonary arterial hypertension. While it is known that… Expand
Review
2012
Review
2012
In spite of treatment, severe angioproliferative pulmonary arterial hypertension (PAH) remains a disease characterized by great… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
AIM To explore the effect of VEGF inhibitor SU5416 on podocytopathy of rats with type I diabetic nephropathy. METHODS Thirty… Expand
2007
2007
Potential prodrugs of inhibitors of VEGF-induced angiogenesis have been investigated. The prodrug systems studied were the 4… Expand
Review
2006
Review
2006
SU5416, 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, is a potent inhibitor of vascular endothelial growth… Expand
2005
2005
SummaryVascular endothelial growth factor (VEGF) is a potent stimulant of angiogenesis. SU5416, is a small molecule tyrosine… Expand
  • table 2
  • table 1
  • table 3
  • table 4
2004
2004
SU5416 is a selective inhibitor of vascular endothelial growth factor (VEGF) receptor, which plays a major role in vascular… Expand
2000
2000
SU5416 [3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1, 3-dihydro-indol-2-one], an inhibitor of VEGF (vascular endothelial growth… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4